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There is considerable interest[1] in the possibility that a virus may be contributing to the 
aetiology of human breast cancer, with previous and ongoing work focusing on Epstein-
Barr virus, human papillomavirus and a number of other candidates, including newly 
identified viruses present in dairy products (eg[2]). Recent work has suggested that 
bovine leukaemia virus (BLV) may be a risk factor for human breast cancer[3]. This 
deltaretrovirus of cattle causes B cell leukaemia in around 5% of infected hosts, is 
present in a large proportion of commercial dairy and beef herds, and is shed in milk 
(but inactivated by pasteurisation). The position of BLV in the pantheon of retroviruses 
linked to human cancers is, at present, controversial. 
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A number of retroviruses can cause or contribute to cancer in humans, with the clearest 
evidence found in simian retroviruses which have jumped the species barrier into 
humans. Human T lymphotropic viruses I and II (HTLV-I and HTLV-II) evolved from 
simian T lymphotropic viruses which infected humans as zoonoses and over time 
adapted to their human hosts. Transmitting horizontally and vertically between humans, 
HTLV-I causes cancer in a small number of infected individuals, and HTLV-II is 
associated with increased cancer risk[4]. HIV-1 indirectly promotes cancer development 
by reducing immune surveillance, particularly predisposing HIV-positive individuals to 
virus-driven cancers such as Kaposi’s sarcoma. There is a long-standing interest in the 
potential role of other mammalian retroviruses in human oncogenesis[5]. Could BLV be 
the next retrovirus to join this list? 
Recent reports have produced conflicting evidence for a link between BLV and human 
cancer. Buehring and colleagues compared healthy and diseased human mammary 
epithelial tissue, and found 29% of healthy, 38% of pre-malignant and 59% of malignant 
mammary epithelial samples to be BLV positive. This builds on earlier work showing the 
presence of BLV in the mammary epithelial cells of cattle[6]; and antibodies to BLV in 
human blood donors[7]. Consequently, the group propose BLV positivity as a risk factor 
for breast cancer. Buehring et al used in-situ PCR and immunohistochemistry to study 
formalin-fixed paraffin embedded (FFPE) mammary epithelial. Unfortunately, FFPE 
samples often give poor-quality, degraded DNA, which has made sequence analysis of 
the BLV present in these sample difficult; at present, the group have not published the 
sequences recovered, although they report that they are different to the control 
sequence used by the lab[8]. In contrast to this, RNA-seq analysis of 4433 tumours from 
19 cancer types found no evidence of known or novel viruses infecting human breast 
cancers[9]. Similarly, retrovirus-specific enrichment of tumour samples[10] found no 
evidence of retroviral infections in human B cell lymphomas (where BLV might be found, 
given BLVs role in bovine B cell leukaemia); and exome sequencing and RNAseq of 
breast cancer FFPE samples from Belgium also found no evidence of BLV or other 
retroviruses[11]. Conversely, a multi-pathogen probe-based array found evidence of 
retroviruses in a proportion of screened FFPE breast cancer samples[12], as well as 
other viral and bacterial pathogens. If BLV is present in human breast cancer, these 
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conflicting findings could be explained by a number of different factors: BLV may only 
be present in breast cancer tissue at very low levels; it may be transcriptionally silent; or 
BLV may only be found in breast cancers from geographically-restricted areas. 
Other non-human retroviruses have been linked to breast cancer. One of the longest-
standing candidates for a viral cause of human breast cancer is mouse mammary 
tumour virus (MMTV), first identified as an extrachromosomal cause of murine 
mammary gland cancer in 1933[13], transmitted in milk. MMTV established the model of 
viral oncogenesis in breast cancer, and ever since scientists have searched for an 
analogous virus in humans. Decades of studies have generated a body of literature that 
is highly suggestive of a human analogue, but lacks definitive proof of its existence. 
Ultrastructural studies identified MMTV-like particles in human breast cancer 
samples[14] and in human breast milk[15]. More recently, genetic and molecular 
methods have been used but they have not resolved the controversy that surrounds 
MMTV and a putative human mammary tumour virus. A key difficulty with molecular 
studies is the presence in the human genome of human endogenous retroviruses 
(HERVs) with significant homology to MMTV. As a result, since the mid-1990s studies 
have used primers complementary to regions of the MMTV genome with low homology 
to known HERVs, commonly targeted to the env region of MMTV which has just 16% 
homology to HERVK-10, the most closely related HERV. A recent systematic review of 
these refined molecular studies concluded that, while many studies detected MMTV env 
sequences in malignant tissue, various methodological flaws meant that none of the 
studies with a positive result were convincing[16].  
Fimereli et al. harnessed multiple in silico techniques to analyse breast cancer 
transcriptomes for viral gene expression, and concluded that no viruses were expressed 
highly enough to be considered causative, furthermore MMTV-like sequences were not 
detected[11]. As discussed above, RNAseq and deep sequencing studies of breast 
cancer samples have produced mixed support for the presence of a retrovirus in human 
breast cancer. However, as has been suggested for BLV, viral gene expression may not 
be necessary for MMTV oncogenesis. The story of MMTV or a human mammary 
tumour virus as oncogenic agents in human breast cancer remains unfinished: despite 
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over 40 years of research, nobody has delivered definitive proof. Indeed it is a lesson in 
the challenges of generating irrefutable evidence of causation, many of which will likely 
apply to BLV. 
Trying to identify new pathogens that contribute to human oncogenesis is a fraught 
process, and a cautionary tale involves another mammalian retrovirus. In 2006, a 
murine leukaemia virus (MLV), xenotropic murine leukaemia virus-like retrovirus 
(XMRV), was detected in prostate cancer biopsies from men with mutations in gene 
RNASEL[17]. Later, XMRV and related MLVs were detected in the blood of people with 
chronic fatigue syndrome, although those studies were later retracted. A careful and co-
ordinated international effort identified that XMRV and MLVs were detected in cancer 
biopsies[18], cell lines[19] and chronic fatigue syndrome blood samples[20] due to 
laboratory contamination from a range of sources[21, 22]. Murine-derived laboratory 
reagents are not the only source of contaminating viral and bacterial material: multiple 
studies have found laboratory kits, reagents and even water supplies to be 
contaminated with a wide range of nucleic acids[23, 24]. As molecular methods become 
more sensitive, the risk of very low level contamination generating false-positive results 
grows. PCR may be particularly sensitive to this problem.  
The story of XMRV’s rise and fall as a possible human pathogen has a number of 
important lessons for the study of BLV in human breast cancer. Molecular genetic 
screening, careful use of control samples, and stringent checks for contamination will be 
required to identify whether BLV is circulating in the human population. Detection of 
BLV in blinded samples analysed at multiple laboratories, ideally from different tissue 
collections sourced from different geographical areas would be key to gaining support 
for BLVs involvement in breast cancer.  
Although not essential, identification of BLV in breast cancer through unbiased methods 
such as RNAseq or cancer exome sequencing would provide additional evidence. 
Analysis of microRNAs (miRs) may provide a further method for detecting putatively 
BLV-infected breast cancers. BLV is unusual among viruses in expressing miRs, which 
are more commonly associated with DNA viruses. One of the better-characterised BLV 
miRs (BLV-miR-B4) has properties associated with B cell tumorigenesis in a mouse 
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model. Low BLV mRNA and protein expression in infected bovine cells may also be a 
property of zoonotic BLV infections[25], reducing the chance of detection by methods 
such as RNAseq. In light of this, examination of the miR profiles of human breast 
cancers for retroviral miRs is a further productive avenue of research. 
Future perspectives on BLV and breast cancer studies 
The possibility of a novel mammalian retrovirus driving a proportion of human breast 
cancers continues to be contentious, whether the candidate is of bovine, murine or 
human origin. Distinguishing novel or rare human pathogens from laboratory artefacts 
will require extensive replication efforts. If the presence of BLV in human breast cancer 
can be unambiguously identified, further, larger case-control studies such as the one 
conducted by Buehring and colleagues[3] would clarify whether BLV is a risk factor or 
biomarker for breast cancer. The lessons of the XMRV story show how quickly an 
international, collaborative effort can characterise the molecular origins of a novel virus 
if there is sufficient interest among the scientific community. Until that time, BLV’s 
identity as a human tumour virus or human ‘rumour virus’ remains unclear. 
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